NASDAQ: PRAXPraxis Precision Medicines Inc Stock
$63.02+3.64 (+6.13%)
Updated Sep 19, 2024
PRAX Price
$63.02
Fair Value Price
$13.41
Market Cap
$1.12B
52 Week Low
$13.01
52 Week High
$67.21
P/E
-6.87x
P/B
2.67x
P/S
439.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.77M
Earnings
-$123.74M
Gross Margin
100%
Operating Margin
-6,987.01%
Profit Margin
-6,987%
Debt to Equity
0.05
Operating Cash Flow
-$95M
Beta
1.15
Next Earnings
Nov 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PRAX Overview
Praxis Precision Medicines, Inc. is developing therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, a treatment for major depressive disorders and perimenopausal depression, and PRAX-944, for the treatment of essential tremor. Praxis Precision Medicines was incorporated in 2015 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRAX ($63.02) is overvalued by 370.02% relative to our estimate of its Fair Value price of $13.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PRAX ($63.02) is not significantly undervalued (370.02%) relative to our estimate of its Fair Value price of $13.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PRAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRAX due diligence checks available for Premium users.
Be the first to know about important PRAX news, forecast changes, insider trades & much more!
PRAX News
Valuation
PRAX fair value
Fair Value of PRAX stock based on Discounted Cash Flow (DCF)
Price
$63.02
Fair Value
$13.41
Overvalued by
370.02%
PRAX ($63.02) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRAX ($63.02) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.87x
Industry
-135.85x
Market
25.52x
PRAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.67x
Industry
6.51x
PRAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRAX's financial health
Profit margin
Revenue
$357.0k
Net Income
-$32.7M
Profit Margin
-9,153.2%
PRAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PRAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$441.1M
Liabilities
$22.0M
Debt to equity
0.05
PRAX's short-term assets ($356.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRAX's short-term assets ($356.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.3M
Investing
-$195.9M
Financing
$216.4M
PRAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRAX vs Biotech Stocks
Praxis Precision Medicines Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.